More on Semaglutide in Early Type 1 Diabetes

To the Editor: In an uncontrolled case series, Dandona et al. (Sept. 7 issue) 1 treated 10 patients with new-onset type 1 diabetes with the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide. Prandial insulin could be discontinued in all the patients, and basal insulin could be discontinued in 7 of 10. These results contrast with the negative results of an earlier randomized, controlled trial investigating the less potent GLP-1 receptor agonist liraglutide in patients with new-onset type 1 diabetes. 2 Dandona et al. restricted carbohydrate intake in their patients. Some positive effects of carbohydrate restriction on glycemic control in patients with type . . .